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Abstract Purpose: Neuromuscu-
lar abnormalities are common in ICU
patients. We aimed to assess the
incidence of clinically diagnosed
ICU-acquired paresis (ICUAP)
and its impact on outcome.
Methods: Forty-two patients with
systemic inflammatory response syn-
drome on mechanical ventilation for
C48 h were prospectively studied.
Diagnosis of ICUAP was defined as
symmetric limb muscle weakness in
at least two muscle groups at ICU
discharge without other explanation.
The threshold Medical Research
Council (MRC) Score was set at 35
(of 50) points. Activities in daily
living were scored using the Barthel
Index 28 and 180 days after ICU
discharge. Results: Three patients
died before sedation was stopped. I-
CUAP was diagnosed in 13 of the
39 patients (33%). Multivariate
regression analysis yielded five ICU-
AP-predicting variables (P \ 0.05):
SAPS II at ICU admission, treatment
with steroids, muscle relaxants or
norepinephrine, and days with sepsis.
Patients with ICUAP had lower
admission SAPS II scores [37 ± 13
vs. 49 ± 15 (P = 0.018)], lower
Barthel Index at 28 days and lower
survival at 180 days after ICU dis-
charge (38 vs. 77%, P = 0.033) than
patients without ICUAP. Daily TISS-
28 scores were similar but cumulative
TISS-28 scores were higher in
patients with ICUAP (664 ± 275)
than in patients without ICUAP
(417 ± 236; P = 0.008). The only
independent risk factor for death
before day 180 was the presence of
ICUAP. Conclusions: A clinical
diagnosis of ICUAP was frequently
established in this patient group.
Despite lower SAPS II scores, these
patients needed more resources and
had high mortality and prolonged
recovery periods after ICU discharge.
Keywords ICU-acquired paresis
(ICUAP)  Systemic inflammatory
response syndrome (SIRS) 
Multiorgan failure (MOF) 
Mechanical ventilation  Prolonged
weaning  Barthel Index
Introduction
Critical illness polyneuropathy (CIP) is an acute diffuse
neuropathy resulting from axonal dysfunction in critically
ill patients [1–4]. Since the first description by Bolton [1, 4],
further studies have documented the clinical, electrophys-
iological and morphological features [5–10]. Studies
suggest that patients with suspected CIP may in fact have a
myopathy as a contributing if not primary cause of the
muscle weakness [11–13]. The diagnosis of both poly-
neuropathy and myopathy in the ICU has relied on
electrophysiological or histological examinations. Conse-
quently, the clinical equivalent of CIP is described as ICU-
acquired paresis (ICUAP) [14]. Nevertheless, the
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specificity of a clinical diagnosis of ICUAP has been con-
firmed using neurography and muscle biopsy [14]. In this
seminal study, an association was found between clinical
signs of muscle weakness and prolonged mechanical ven-
tilation. Patients were included when on mechanical
ventilation for 7 or more days and if awake. Similarly, a
recently published study in patients on mechanical venti-
lation for 5 or more days found an association between
ICUAP and length of mechanical ventilation, length of
hospital stay and mortality [15]. However, a recent sys-
tematic review including data from almost 1,500 patients
could not confirm an association between ICUAP and
short-term mortality [16]. We aimed at extending existing
data to cover both the early ICU phase and the conse-
quences of clinically diagnosed ICUAP after the ICU stay.
The specific aims of this study were (1) to perform
repeated clinical assessments for the presence of ICUAP
starting as early as 48 h after ICU admission in
mechanically ventilated patients with systemic inflam-
mation, even if uncooperative, and (2) to evaluate
resource use as estimated by TISS-28 scores and length of
mechanical ventilation and ICU stay, functional integrity
6 months after ICU discharge, and severity of disease-
adjusted mortality when compared to patients without
ICUAP. We hypothesized that a clinical diagnosis of
ICUAP is associated with prolonged mechanical ventila-
tion and ICU stay, increased resource use at ICU
discharge, and delayed recovery, even when the diagnosis
has not been confirmed with electrophysiological tests.
This study was presented in part at the ESICM Congress
in Berlin, Germany, in 2007 [17].
Patients and methods
This study was approved by the Ethics Committee of the
Canton of Bern. The presumed will of the patients needed
to be expressed by a close relative before study inclusion,
and deferred written informed consent was obtained from
patients. In addition, an independent physician confirmed
inclusion and exclusion criteria. Between September 2005
and May 2006, all mechanically ventilated patients stay-
ing in the ICU for 48 h were screened for the presence or
absence of C2 systemic inflammatory response syndrome
(SIRS) criteria [18]. Exclusion criteria are listed in the
Electronic supplementary material (ESM).
Demographic variables and main diagnosis were
recorded and Simplified Acute Physiological Score II
(SAPS II) [19] was calculated at admission, and
Sequential Organ Failure Assessment Score (SOFA) [20]
was calculated at days 1, 3 and 7 after study inclusion and
at ICU discharge. The therapeutic Intervention Scoring
System (TISS-28) was recorded daily until ICU discharge
as a surrogate for resource expenditure. The presence or
absence of sepsis and/or SIRS was recorded on a daily
basis. Protocols for cardiovascular management, sedation
and weaning have been published previously [21]. Defi-
nition of sepsis, treatment of the patients and data
recording are indicated in the ESM.
Neurological examinations
The Richmond Agitation/Sedation Scale (RASS) [22] was
recorded every 2–4 h, and the Glasgow Coma Scale
(GCS) [23] daily after stop of sedation, if performed.
Neurological examinations were performed each day after
sedation stop and included assessment of muscle strength
of ten muscle groups (upper extremities: wrist flexion,
forearm flexion, shoulder abduction; lower extremities:
knee extension, hip flexion), as well as assessment of skin
sensation (upper and lower extremities) and tendon
reflexes (biceps, triceps, patellar and achilles). The pres-
ence of ICUAP was diagnosed according to the Medical
Research Council (MRC) Score, whose inter-rater reli-
ability has been confirmed [24]. Using this score, full
muscle strength results in 5 points (M5) per tested muscle.
A clinical diagnosis of ICUAP was made when weakness
(BM3) was diffuse, bilateral, involving upper and lower
extremities, and resulted in a [30% reduction in MRC
score (\35 points), independent of presence or absence of
sensitivity disturbance or reduced tendon reflexes.
The clinical course of the patients was followed until
hospital discharge. At day 28 after ICU discharge, all
surviving patients were contacted (by phone call if dis-
charged from hospital), and their fitness was assessed
using the Barthel Index [25]. Six months after ICU dis-
charge, the patients were invited to the clinic for an
interview and a clinical neurological assessment.
Statistics
The detailed statistical approach is indicated in the ESM.
Diagnosis of ICUAP required the presence of ICUAP cri-
teria at ICU discharge. For the comparison between patients
with and without clinical ICUAP, categorical variables were
analyzed using the chi-square or the Fischer exact test, and
quantitative data using the unpaired Student’s t test. Survival
was described by Kaplan–Meier curves. Risk factors for
ICUAP and for 180-day mortality were determined using
multivariate regression analysis. Categorical data are pre-
sented as numbers (percentages), and quantitative data as
mean ± SD. A P value of\0.05 was considered significant.
Results
Between September 2005 and May 2006, 210 patients
were screened, and 42 patients were included between
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day 3 and 13 after ICU admission (Fig. 1). Three patients
were continuously sedated and died before a clinical
evaluation of muscle strength was possible. Thirteen of
the 39 evaluated patients (33%) met the clinical criteria
for ICUAP at ICU discharge.
Demographics
Demographic data are displayed in Table 1. The main
ICU admission diagnoses were elective and emergency
cardiac surgery and heart failure. SAPS II at ICU
admission was lower in patients who developed clinical
ICUAP (37 ± 13 vs. 49 ± 15, P = 0.018). At study
entrance (48 h after ICU admission), this difference dis-
appeared (52 ± 13 vs. 51 ± 19, P = 0.865).
Treatment of the patients
For detailed information, see ESM. Steroid, muscle
relaxant and catecholamine treatment is indicated in
Table 2. Insulin administration and glycemic control are
reported in Table 2. There were no differences between
patients with and without ICUAP.
SIRS, sepsis and multiple organ dysfunction
Days of SIRS and days of sepsis were significantly higher
in patients with ICUAP (10 ± 5 vs. 5 ± 5, P = 0.003
and 2 ± 3 vs. 1 ± 1, P = 0.003, respectively; Table 2).
SOFA scores were similar in the two groups at day 1
(9 ± 3 vs. 9 ± 2). Multiple organ failure, defined as C2
failing organs, was present in all but one patient without
ICUAP at some time point during the ICU stay, but SOFA
scores were higher on day 7 in patients with ICUAP
(9 ± 3) when compared to patients without ICUAP
(6 ± 3; P = 0.043).
Neurological findings
GCS and RASS scores are indicated in Table 3. On the
day of discharge from the ICU, 13 patients had a clinical
diagnosis of ICUAP (33%; Table 4). Detailed neurolog-
ical findings are indicated in the ESM.
Screened
N=210
Exclusion criteria
N=126
Inclusion criteria
N=84
Extubated <48h
N=76
Neurol. diseases
N=31
Informed consent
lacking/other study
N=40
Included
N=44
Miscellaneous*
N=19
Secondary
exclusion
N=2
Discharged <48h
N=1Evaluated
N=42
ICUAP neg
N=26
Neuromusc. 
function not 
measurable
N=3
Withdrawal
of informed
consent
N=1
Day 28: 6 pat died (3 in ICU, 3 after ICU), 2 pat missed clinical
follow up, leaving N=5
ICUAP pos
N=13
Day 180: 8 pat died (3 in ICU, 5 after ICU), 1 pat missed clinical
follow up, leaving N=4
Day 28: 5 pat died (1 in ICU, 4 after ICU), 3 pat missed clinical
follow up, leaving N=17
Day 180: 5 pat died (1 in ICU, 4 after ICU), 2 pat missed clinical
follow up, leaving N=18
Fig. 1 Screened, included and excluded patients. N = patients included or clinically examined. Miscellaneous exclusion criteria denoted
by asterisks were: liver cirrhosis, human immunodeficiency virus infection, renal disease and peripheral arterial occlusion disease
68
Mechanical ventilation, length of ICU stay
and resource use
Patients were ventilated for 9 ± 6 days and stayed in the
ICU for 12 ± 7 days. Patients with clinical ICUAP
remained significantly longer on mechanical ventilation
and in the ICU (Fig. 2).
Neither TISS-28 scores at admission (Table 1), day 3
and day 7, nor mean daily TISS-28 scores (patients with
ICUAP 40 ± 4, patients without ICUAP 42 ± 10;
P = 0.477) differed between groups. The cumulative
TISS-28 score was significantly higher in patients with
ICUAP (664 ± 275) than in patients without ICUAP
(417 ± 236) (P = 0.008).
Functional outcome and survival
The 180-day survival was significantly higher in patients
without clinical ICUAP (77 vs. 38%, respectively,
P = 0.033; v2 test) (Fig. 3).
The Barthel Index was lower in patients with ICUAP
as compared to the other patients (43 ± 21 vs. 81 ± 24;
P = 0.011) (Fig. 4). 180 days after discharge, the
Table 1 Demographics, severity of illness and diagnoses in all patients, and in patients with and without a diagnosis of ICU-acquired
paresis (ICUAP)
All patients
(n = 39)
Patients with
ICUAP (n = 13)
Patients without
ICUAP (n = 26)
P-value
Age (years) 67 ± 14 70 ± 16 65 ± 13 0.352
Male [n (%)] 28 (70) 7 (54) 21 (81) 0.591
Female [n (%)] 11 (30) 6 (46) 5 (19) 0.293
SAPS II 45 ± 15 37 ± 13 49 ± 14 0.015
SOFA first day 9 ± 2 9 ± 3 9 ± 2 1.000
TISS-28 at admission 37 ± 9 37 ± 11 37 ± 9 0.619
Surgical diagnosis [n (%)] 17 (43) 8 (62) 9 (35) 0.378
Major surgery [n (%)] 7 (18) 3 (23) 4 (15) 0.681
Cardiac surgery [n (%)] 10 (26) 5 (38) 5 (19) 0.465
Medical diagnosis [n (%)] 20 (51) 5 (38) 15 (58) 0.565
Infections-sepsis [n (%)] 7 (18) 2 (15) 5 (19) 1.000
Gastrointestinal [n (%)] 2 (5) 1 (8) 1 (4) 1.000
Cardiovascular [n (%)] 9 (23) 1 (8) 8 (31) 0.25
Lung [n (%)] 2 (5) 1 (8) 1 (4) 1.000
Trauma [n (%)] 2 (5) 0 2 (8) 0.544
Values are mean ± SD, numbers or percentages
Table 2 Exposures to drugs, glycemic control and days of SIRS and sepsis
All patients
(n = 39)
Patients with
ICUAP (n = 13)
Patients without
ICUAP (n = 26)
P-value
Steroids [n (%)] 4 (10) 4 (31) 0 0.009
Muscle relaxants [n (%)] 10 (26) 7 (54) 3 (11) 0.008
Catecholamines [n (%)] 28 (72) 13 (100) 15 (58) 0.007
Norepinephrine [n (%]) 17 (44) 10 (77) 7 (27) 0.005
Insulin, daily dose (U) 24 ± 22 25 ± 19 23 ± 24 n.s.
Insulin, cumulative dose (U) 411 ± 381 466 ± 288 377 ± 433 n.s.
Hypoglycemiaa (%) 2.9 ± 2.9 3.6 ± 3.2 2.5 ± 2.7 n.s.
Severe hypoglycemiab (%) 0.1 ± 0.2 0.1 ± 0.3 0.1 ± 0.2 n.s.
Hyperglycemiac (%) 24.0 ± 12.6 21.1 ± 7.9 24.6 ± 14.4 n.s.
Severe hyperglycemiad (%) 4.5 ± 4.9% 3.8 ± 2.5 4.7 ± 5.8 n.s.
Days with SIRS 7 ± 5 10 ± 5 5 ± 5 0.002
Sepsis [n (%)] 17 (44) 8 (61) 9 (35) n.s.
Days with sepsis 1 ± 2 2 ± 3 1 ± 1 0.003
Values are numbers, percentage or mean ± SD. Total 3,845 glu-
cose checks
a Hypoglycemia is defined as blood glucose \4.5 mmol/l
b Severe hypoglycemia is defined as blood glucose \3 mmol/l
c Hyperglycemia is defined as blood glucose [7 mmol/l
d Severe hyperglycemia is defined as blood glucose [10 mmol/l
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Barthel Index had improved in all patients. For details
see ESM.
Risk factors for ICUAP and death before day 180
Based on the significant associations and clinical rele-
vance of all results (see ESM), the following 11 variables
were chosen for multivariate regression analysis with
ICUAP as the dependent variable: SAPS II at ICU
admission, SOFA subscore GCS on day 1, ICU LOS,
days on mechanical ventilation, days with SIRS, days
with sepsis, treatment with steroids, treatment with
muscle relaxants, days with muscle relaxation, treatment
with any catecholamine and treatment with norepineph-
rine. This yielded five ICUAP-predicting variables
(P \ 0.05): SAPS II at ICU admission, steroid treatment,
days with sepsis, treatment with muscle relaxants and
norepinephrine treatment. The coefficients of the esti-
mated regression model are presented in Table 5. The
model statistics are presented in the ESM. Since ICU
admission-SAPS II was unexpectedly lower in patients
with ICUAP, the model was also tested without this
variable. Here, the best predicting model consisted of the
Table 3 Minimal and maximal GCS and RASS scores at day 1 and at discharge from the ICU
Assessment GCS–RASS All patients
(n = 39)
Patients with
ICUAP (n = 13)
Patients without
ICUAP (n = 26)
Day 1 GCS 15 11 (28) 6 (46) 5 (19)
GCS 13–14 16 (41) 6 (46) 10 (38)
GCS 10–12 6 (15) 1 (8) 5 (19)
GCS 6–9 6 (15) 0 6 (23)
GCS \6 0 0 0
Discharge GCS 15 14 (36) 3 (23) 11 (42)
GCS 13–14 16 (41) 6 (46) 10 (38)
GCS 10–12 5 (13) 3 (23) 2 (8)
GCS 6–9 3 (8) 1 (8) 2 (8)
GCS \6 1 (2) 0 1 (4)
Day 1
Max RASS 0 to -1 8 (21) 3 (23) 5 (19)
RASS C1 21 (54) 4 (31) 17 (65)
RASS B-2 10 (26) 6 (46) 4 (15)
Min RASS 0 to -1 3 (8) 1 (8) 2 (8)
RASS C1 1 (2) 0 1 (4)
RASS B-2 35 (88) 12 (92) 23 (88)
Discharge
Max RASS 0 to -1 21 (54) 5 (38) 16 (61)
RASS C1 17 (43) 8 (61) 9 (35)
RASS B-2 1 (2) 0 1 (4)
Min RASS 0 to -1 26 (67) 7 (54) 19 (73)
RASS C1 9 (23) 0 0
RASS B-2 13 (33) 6 (46) 7 (27)
Values are numbers (%). Due to the small numbers per group, statistical tests were not performed
Table 4 Neurological findings according to the Medical Research Council (MRC)
Measured MRC Estimated MRC MRC not
assessable
Discharged
or died
Total number
of patients
\35 [35
Day 1
ICUAP? 20 (4–34) n = 3 1 1 8 13
ICUAP- 34 (8–40) n = 9 5 3 9 26
Day 3
ICUAP? 25 (11–36) n = 6 2 0 5 13
ICUAP- 39 (0–50) n = 16 3 0 4 3 26
Day 7
ICUAP? 23 (18–44) n = 4 5 1 1 2 13
ICUAP- 50 (48–50) n = 5 1 3 1 16 26
Discharge
ICUAP? 26 (0–34) n = 11 2 0 0 13
ICUAP- 42 (37–50) n = 22 0 4 0 26
Values are median (range) and numbers
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independent variables days with sepsis, steroid treatment
and norepinephrine treatment only.
Using the same 11 variables and additionally ICUAP,
with death before day 180 as the dependent variable, the
only independent risk factor turned out to be the presence
of ICUAP (P = 0.009; for model summary and coeffi-
cients see ESM).
Discussion
The present study demonstrates that a simple clinical
neurological assessment alone at ICU discharge is capable
of identifying patients at risk of high morbidity and
mortality, and long-term sequelae for the quality of life.
ICUAP is an incapacitating consequence of critical ill-
ness, and a major burden for the patients and the health-
care system. Although the number of patients is small, the
resources needed for treatment are disproportionate: a
conservative estimate based on our previous data on
resource utilization of prolonged intensive care [26]
suggests that at least 20% of all intensive care resources
are used for the care of these patients. In the present
study, cumulative TISS-28 scores were 50% higher in
patients with ICUAP. This was not explained by more
intensive treatment but by the increased length of stay,
which in turn was a consequence of prolonged need for
mechanical ventilation. Furthermore, ICUAP has long-
term sequelae that impair the patients’ quality of life long
after ICU discharge.
Previous studies have indicated that the diagnosis of
ICUAP can be made without such confirmatory tests as
neuro- and myography with reasonable sensitivity [14,
15]. Both DeJonghe [14] and Ali [15] found an associa-
tion between clinical signs of muscle weakness, including
hand grip strength, and prolonged ICU length of stay,
ventilator dependency and mortality. We found that on
the day of discharge from the ICU, ICUAP was diagnosed
in 33% of these patients.
Muscle weakness during clinical evaluation has been
described in 25–30% of patients receiving intensive care
after 4–7 days of mechanical ventilation [14, 27, 28].
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Fig. 4 Functional outcome [Barthel Index (range 0–100)]. Time in
days after ICU discharge. ICUAP? Patients with ICUAP, ICUAP-
patients without ICUAP
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Clinical assessment of muscle strength is inherently dif-
ficult in ICU patients due to sedation and the patient’s
frequent inability to fully cooperate. We therefore added
an estimate of the muscle strength in patients unable to
cooperate based on the strength and symmetry of their
spontaneous movements during the sedation stop.
Although less precise, this allowed estimation of the
muscle strength earlier during intensive care. In contrast
to other studies [14], in our study the number of patients
in whom clinical assessment of muscle strength or a
reasonable estimate thereof was never practicable was
small (3 out of 42).
In most previous investigations, ICUAP was diag-
nosed by using electrophysiological tests [2, 29–33].
Whether clinical or electrophysiological testing is the
preferred diagnostic method for ICUAP is a matter of
discussion. We agree with the statement of Morris [34]
that there are only a few reasonable indications for elec-
trophysiological tests in patients with a diagnosis of
ICUAP, mainly because of limited therapeutic options in
the acute phase. Recent evidence suggests, on the other
hand, that electrophysiological testing may help to predict
the long-term prognosis by differentiating between
patients with myopathy and neuropathy [35]. In view of
the necessity for prolonged rehabilitation after ICU stay,
any evaluation of patients for the presence of ICUAP
seems mandatory. We suggest that bedside assessment of
muscle strength can easily be done during the daily
sedation stop to screen for signs of ICUAP.
Multivariate regression analysis showed that SAPS II
at ICU admission, steroid treatment, days of sepsis, days
on muscle relaxants and norepinephrine treatment, but not
resource use (TISS-28) were associated with ICUAP in
our patient cohort. The association between initial
severity of illness and ICUAP is controversial. Our find-
ing of lower admission SAPS II scores in patients with
subsequent ICUAP was unexpected. This is probably
related to case mix. The SAPS II score loses its predictive
value for hospital outcome in patients requiring prolonged
intensive care [36]. Furthermore, our sample included a
relevant number of patients admitted after elective sur-
gery, who were initially stable with low SAPS II scores,
but whose stay in the ICU was prolonged due to com-
plications developing later. It is therefore conceivable that
with such a case mix the initial SAPS II scores have no
association with the risk of prolonged ICU stay and
development of ICUAP. Despite the high incidence of
ICUAP, the etiological role of presumed risk factors is
still unclear. In contrast to previous findings [14], female
gender was not a risk factor for ICUAP in our rather small
study.
Patients with ICUAP had a prolonged need for
mechanical ventilation [31, 37–39]. It has been demon-
strated that ICU-associated paresis is an independent
predictor of prolonged weaning from mechanical venti-
lation [38]. In addition, both respiratory and limb muscle
strength are altered after 1 week of mechanical ventila-
tion [37]. However, there is still a lack of data regarding
early, prospective evaluation of diaphragmatic and phre-
nic nerve functions in patients at risk of developing
ICUAP.
There is no agreement in previous studies on mortality
in patients with versus without critical illness polyneu-
ropathy. Garnacho-Montero [31] reported ICU mortality
of 20% in patients with ICUAP as compared to 10% in
patients without (n.s.). In contrast, in the study by Leijten
[32], the ICU mortality was 48% in patients with ICUAP
versus 19% in patients without (P = 0.03). These dis-
crepancies may suggest differences in case mix and
diagnosis of ICUAP. In our study, clinical ICUAP was
associated with decreased cumulative survival until
6 months after discharge from ICU. Most of the patients
in both groups died at the hospital from the underlying
illness within the first 28 days after discharge from the
ICU.
In survivors with clinical ICUAP, the long-term
functional outcome improved during the first 6 months
after discharge from the ICU. This suggests the necessity
and usefulness of referring such patients as early as pos-
sible to specialized rehabilitation facilities. For prognostic
estimates, length of mechanical ventilation and ICU stay,
and presence or absence of ICUAP may have an impor-
tant impact in this group of patients.
A limitation of this study is the lack of confirmatory
electrophysiological tests for ICUAP as a true gold stan-
dard. We did not systematically exclude specific diseases
such as demyelinating polyneuropathy by lumbar punc-
ture and neurophysiological assessments. However, rapid
development of this disease in the ICU—without prior
symptoms—is extremely unlikely.
Table 5 Coefficients and significances of the estimated regression with ICUAP as the dependent variable
Unstandardized coefficients Standardized coefficients t Sig.
B Std. error Beta
SAPS II -0.009 0.003 -0.304 -3.482 0.001
Treatment with steroids 0.779 0.136 0.515 5.745 0.000
Days with sepsis 0.104 0.027 0.395 3.901 0.000
Treatment with norepinephrine 0.249 0.091 0.264 2.726 0.010
Treatment with muscle relaxation 0.226 0.097 0.206 2.326 0.027
72
Furthermore, we used a simplified form of the MRC
score with a reduced number of muscle groups to be tested,
and the cutoff score for the clinical diagnosis of ICUAP was
set arbitrarily at 35. Therefore, the results are not directly
comparable to those of others. However, there is no
agreement in the literature on the correct cutoff score for
the diagnosis of ICUAP. De Jonghe [37] described ‘‘limb
weakness’’, and divided the MRC findings into thirds (0–
28, 29–46, 47–60). Bednarik [40] defined quadriplegia or
quadraparesis with MRC\2 as unequivocal clinical signs
of ICUAP. Zifko [41] set the threshold at an MRC score\3
without indicating muscle groups. In an earlier study, De
Jonghe [14] set the cutoff point at 48 of 60 points according
to the standard MRC scale. We cannot exclude that more
patients would have fulfilled criteria for ICUAP with a full
clinical and neurophysiological examination. Also, by
establishing a clinical diagnosis of ICUAP at ICU dis-
charge only, we may have overlooked some cases with
early, rapidly improving ICUAP. Furthermore, in a sub-
stantial number of patients, the MRC score was estimated
rather than measured because not all patients were coop-
erative enough to allow a detailed and reproducible
examination. At ICU discharge—when the definitive
diagnosis of ICUAP was made—MRC had to be estimated
in 6 out of 39 patients (15%). This approach has not been
validated and may have resulted in an under or overesti-
mation of the incidence of ICUAP at a given time point. We
do not believe that there is a better clinical estimate of
muscle strength in uncooperative patients; nevertheless,
our approach should be validated in further studies. A high
number of patients with preexisting neurological illness
(traumatic brain injury, intracerebral bleeding, subarach-
noidal bleeding) and/or hemispheric processes were
excluded and could not be assessed by a score that required
movement on both sides. Finally, a substantial number of
patients had to be excluded as a consequence of our
inability to obtain informed consent. Whether the included
patients represent the true ICU population with SIRS and
mechanical ventilation [48 h cannot be determined.
Nevertheless, our approach resulted in a clearly definable
patient group with an occurrence rate of ICUAP similar to
other studies, high mortality after ICU discharge and a
prolonged recovery period.
Another limitation is the lack of validation of the
Barthel Index as a score for physical functional outcome
in ICU survivors with acquired muscle weakness, and the
lack of a systematic long-term assessment of cognitive
outcome and quality of life. Further studies should
address these issues and determine the effects of early
specific rehabilitation in patients with clinical ICUAP.
We conclude that using clinical investigations at the
bedside seems to be a simple way to identify a group of
patients with increased mortality and protracted recovery
of physical functions after ICU discharge. This may aid in
recognizing patients in need of long-term rehabilitation.
Accordingly, comprehensive electrophysiological evalu-
ation of patients with ICUAP can be delayed until before
discharge from the acute-care hospital for rehabilitation.
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